International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (769-775), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Systematic Review of Pneumococcal Vaccination of Preterm Infant

[1]Fayez Sulobi Alenezi, [2]Mohana Jabban Alenezi, [3]Fahad Ali AlZahrani, [4]Osama Saleh Alnefisah, [5]Abdullah sulaiman alturaif, [6]Abdulmajeed Mousa saud Al harbi, [7]Abdulaziz Abdullah Aldalbahi, [8]Suhail Mohammed Alzahrani

Abstract: **Streptococcus pneumoniae is among the major bacterial pathogens responsible for a wide spectrum of invasive disease and severe breathing system infections such as community-acquired pneumonia, intense otitis media, bacteremia, and meningitis, specifically in children younger than 2 years in both developing and industrialized countries. Therefore, the goal of this systematic review study was to evaluate the Pneumococcal Vaccination of Preterm Infant from different perspectives, including benefits, mortality, efficiency side effects, and international programme for this type of vaccinations. Articles were identified from systematic searches of the PubMed (MIDLINE), Embase and Cochrane Collaboration databases, through the period up to December 2016, Our search included reviews of bibliographic reference lists of identified studies. The literature search covered all years and there was language restriction to English, and only articles with Human subjects, thus animal's models were excluded in this review. PCV13 was well endured in early infants. Different priming schedules resulted in higher IgG concentrations at various times throughout the very first 13 months of life. We believe that such information will be beneficial to those planning or providing pneumococcal vaccines to preterm infants and will allow them to think about this finding in the context of their own immunization programs and epidemiologic circumstance, in other studies PCV-7 immunogenicity among VLBW infants, even the tiniest and least mature infants normally accomplished antibody concentrations much like those explained in full-term infants. The favorable immunogenicity of PCV-7 amongst.**

Keywords: **Pneumococcal Vaccination, Preterm Infant, VLBW.**

1. INTRODUCTION

Premature infants are at increased risk of vaccine-preventable diseases, including a twofold risk of intrusive pneumococcal disease compared to term infants [(1,2,3)]. Streptococcus pneumoniae is among the major bacterial pathogens responsible for a wide spectrum of invasive disease and severe breathing system infections such as community-acquired pneumonia, intense otitis media, bacteremia, and meningitis, specifically in children younger than 2 years in both developing and industrialized countries [(4)]. The high morbidity and mortality rates arising from these diseases [(5)] and the increase of multidrug resistant pneumococcal stress [(6,7)] have actually emphasized the urgent need for intro of reliable vaccines against diseases triggered by S pneumoniae [(8,9)]. Pneumococcal conjugate bacterial vaccines that have the ability to avoid intrusive disease and mucosal infections have been established. In the United States, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics have advised routine administration of a heptavalent pneumococcal conjugate vaccine (PCV-7), which includes the 7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) that are the most prevalent in triggering invasive diseases among children, concurrently with other childhood immunizations for all infants below 2 years too for older kids (aged 2- 5 years) at higher risk of establishing intrusive pneumococcal disease (IPD) [(10,11)]. Over 25% of the 7.6 million deaths happening in children <5 years of age worldwide in 2010 were due to pneumonia, sepsis and meningitis [(12)]. Streptococcus pneumoniae is a leading cause of these diseases, estimated by the World Health Organization (WHO) to kill over 500,000 children in 2008 [(13)]; over 90% of these deaths occur in developing countries. Three licensed pneumococcal conjugate vaccines

(PCVs) include antigens from 7, 10 or 13 of the children less than 5 years of age worldwide in 2010 was because of pneumonia, sepsis and meningitis [12].

The goal of this systematic review study was to evaluate the Pneumococcal Vaccination of Preterm Infant from different perspectives, including benefits, mortality, efficiency side effects, and international programme for this type of vaccinations.

2. METHODOLOGY

Systematic review of eligible studies was conducted based on the international guideline for reviews.

Search Methods:

Articles were identified from systematic searches of the PubMed (MIDLINE), Embase and Cochrane Collaboration databases, through the period up to December 2016, Our search included reviews of bibliographic reference lists of identified studies. The literature search covered all years and there was language restriction to English, and only articles with Human subjects, thus animal's models were excluded in this review. The search through these databases were done using the following medical terms (MeSH) terms combined with text words: ["pneumococcal vaccines/adverse effects" (MeSH) OR "pneumococcal vaccines/contraindications" (MeSH) OR "pneumococcal vaccines/toxicity" (MeSH)] OR [(pneumococcal vaccines) AND (erythema OR induration OR pain OR death OR mortality OR anaphylaxis OR allergic reaction OR rash OR urticaria OR vomiting OR safety OR morbidity OR harm)].

The articles were independently reviewed by the authors, and any disagreement was discussed independently from different studies.

3. RESULTS & DISCUSSION

Immunologic Basis and Host Response to Pneumococcal Vaccines:

Streptococcus pneumoniae is a complex bacterium with ninety-two different polysaccharide capsular serotypes identified to date [14]. The human air passage utilizes many mechanisms to protect from colonization and invasive pneumococcal infection. Inherent immune defenses such as mucociliary escalator and a selection of pattern acknowledgment receptors that recognize bacterial proteins help with the preliminary security against the bacteria [15,16]. The antiphagocytic bacterial capsule is thought about to be the most essential determinant of pneumococcal virulence and is very important for colonization of the nasopharynx [17] (**Figure 1**) [18]. Pneumococcal cell wall pieces and capsular polysaccharides are recognized by antibodies that trigger the complement and bind system [19].



Figure1: Humoral Immunity Clearance of extracellular pathogen [18]

Safety and efficacy of Pneumococcal Vaccination of Preterm Infant:

Several studies have demonstrated the safety and immunogenicity of a 7 valent conjugate pneumococcal vaccine when utilized at different schedules: 2, 4, 6, and 12 months; 3, 5, and 11 months; and 2, 3, and 4 months of age. A recent Italian study discovered no considerable distinction in antibody levels to PCV7 vaccine serotypes between term and preterm infants after a 3 dosage vaccination schedule given at 3, 5 and 11 months [(20)]. Of note, only healthy preterm infants of > 32 weeks' gestation who had not received any blood items or treatment likely to affect the immune response were included in this research study. The large efficacy study of the 7 valent conjugate pneumococcal vaccine in the United States registered only healthy preterm infants (gestational age not specified) who had been released home by 2 months of age. The immunogenicity of all vaccine serotypes were discovered to be higher in preterm than term infants and the efficacy versus intrusive pneumococcal disease was equivalent to that of term infants [(3)]. On the other hand, a UK research study consisted of all preterm infants and vaccine was administered at 2, 3, and 4 months of age. Virtually all preterm infants had post primary antibody concentrations well above the limit anticipated to supply defense against invasive pneumococcal disease. Absolute concentrations were lower in preterm infants than in term infants. These decreased antibody concentrations continued until 1 year of age in addition to after the booster dose, although a memory response was evident in preterm infants [(21)].

The efficacy and immunogenicity of PCV-7 have been evaluated previously in larger early infants. As part of an efficacy study, in which PCV-7 was administered at 2, 4 and 6 months, some 4340 early infants (born at <38 weeks' gestation) and 1756 LBW infants (<2500 grams) were evaluated (3). The vaccine had 100% efficacy in those populations. Just 167 infants <32 weeks and 131 really low birth weight (VLBW) infants were included, and the immunogenicity of PCV-7 in these infants was incompletely attended to. In a study of 46 infants born at 32-- 36 weeks' pregnancy and offered PCV-7 at 3, 5 and 11 months of age, early infants had antibody concentrations comparable to the concentrations of complete term infants following the third vaccine dosage (20). All early infants in that study achieved concentrations ≥ 0.15 μg/ mL versus all 7 vaccine antigens after 3 dosages of vaccine, but that little research study did not consist of extremely preterm infants. In a current research study of a population more just like ours, 69 premature infants, of whom 42 were <32 weeks' gestation at birth, and 68 full-term controls got PCV-7 at 2, 3 and 4 months of age (21). Lower proportions of early infants had concentrations ≥ 0.35 μg/ mL against serotypes 4, 6B and 9V than full-term controls following the primary vaccine series, although both full-term and premature infants responded similarly to a polysaccharide pneumococcal vaccine booster at 12 months old.

Studies of full-term infants receiving PCV-7, no matter schedule, describe greater than 90% of infants attaining concentrations ≥ 0.15-- 0.2 μg/ mL versus each vaccine serotype [(21,22)]. Greater than 90% of full-term infants getting PCV-7 on a sped up 2, 3 and 4-month schedule attain concentrations ≥ 0.35 μg/ mL against all serotypes except 6B (to which 79% achieve these concentrations) [(21)]. Full-term infants receiving PCV-7 on a 2, 4, and 6-month schedule achieve concentrations ≥ 1.0 μg/ mL in proportions varying from 51% (serotype 9V) to 89% (serotype 14), in a pattern similar to that seen among even the most immature infants in the existing study [(22)].

The present research study [(23)] complements previous research studies in recommending that, under situations predisposing to reduced vaccine immunogenicity (e.g. less immunogenic serotypes or sped up vaccine schedules), PCV-7 might be less immunogenic in ELBW (<1000 grams' birth weight) infants. As antibody concentrations decay in time, lower concentrations might end up being scientifically substantial prior to a booster dose of vaccine [(20,21)].

We have identified a multi-center observational research study [(23)] including infants 401-1500 grams' birth weight and <32 0/7 weeks' gestation as its shown in (Table 1) (23), stratified by birth weight, were registered from 9 NICHD Neonatal Research Network centers. Infants received PCV-7 at 2, 4 and 6 months after birth and had actually blood drawn 4-6 weeks following the 3rd dosage. This study showed that only serotypes 6B and 23F showed considerable associations with birth weight on univariate analyses, just these serotypes were examined by several logistic regressions (**Figure 2**) [(23)]. Lower birth weight (serotypes 6B and 23F) and postnatal glucocorticoid administration (serotype 6B only) were each separately associated with antibody concentrations <0.35 μg/mL. Caucasian race (serotype 6B) and lighter weight for corrected age (serotype 23F) also emerged as a factors associated with poorer vaccine immunogenicity, even when controlled for glucocorticoid exposure. Addition of ethnicity, bronchopulmonary dysplasia and/or center to the model or using a cut-off of 0.15 μg/mL did not materially alter the regression results. However, Fifteen children (11 in the ≤1000-gram group and 4 in the ><0.35 μg/ mL[(23)].

Table 1: Baseline and postnatal characteristics of subjects completing study within time window and having serum available (N = 244). [23]

Characteristic	
Birth weight (in grams) (mean ± SD)	1008 ± 282
Gestation (in weeks) (mean ± SD) [range]	27.8 ± 2.2 [23.0, 32.0]
Gender, male	134 (55%)
Race, Caucasian	153 (63%)
Ethnicity, Latino	73 (30%)
Medicaid insurance	114 (47%)
Small for gestational age	32 (13%)
Antenatal glucocorticoids	168 (69%)
Any mechanical ventilation prior to 28 days old	194 (80%)
Bronchopulmonary dysplasia	63 (26%)
Postnatal glucocorticoids prior to hospital discharge	38 (16%)
Culture-proven systemic infection prior to hospital discharge	88 (36%)
Systemic glucocorticoid therapy at time of 1st dose PCV-7	1 (0.4%)
Median age (months) at 1st dose PCV-7 [range]	2.1 [1.4, 3.0]
Median age (months) at 3rd dose PCV-7 [range]	6.2 [5.0, 7.9]
Median age (months) at blood draw [range]	7.4 [6.1, 9.0]
Weight (kg) at 1st dose PCV-7 (mean ± SD)	2.2 ± 0.7
Weight (kg) at blood draw (mean ± SD)	6.5 ± 1.1
Weight-for-corrected-age Z-score at blood draw* (mean ± SD)	−0.5 ± 1.3

Values expressed as N (%), unless otherwise specified.

SD = standard deviation. PCV-7 = heptavalent pneumococcal conjugate vaccine.

*Z-score based on the 2000 CDC growth chart (http://www.cdc.gov/growthcharts/).



Figure 2: Multiple logistic regression for pneumococcal antibody concentration ≥0.35 µg/mL at 4–6 weeks after the third PCV-7 dose. The dependent variable was an antibody concentration ≥0.35 µg/mL. Results are depicted for serotypes 6B (A) and 23F (B). The X axis shows the odds ratio for the effect of each variable, adjusted for all of the other independent variables. Diamonds depict odds ratios and whiskers represent 95% confidence intervals.

Efficient PCV serotypes for preterm infants:

Serotype-specific responses diverse, with lower IgG GMCs achieved for serotypes 3, 5, and 6B after the primary course and for serotypes 3, 9V, and 18C after the booster dose; these findings are consistent with those observed in term infants [23,24]. However, compared with previous term (PCV13) and preterm (PCV7) research studies, antibody concentrations after primary and booster vaccination are lower overall, resulting in lower seroprotection after primary vaccination [21,23,25,26,27]. Likewise, compared with the current PCV13 preterm research study, [28] lower IgG GMCs and seroprotection rates were seen for all serotypes. These differences may be because of the various laboratory testing approaches used for serotype-specific antibody concentrations, however possible biological explanations include interactions with concurrently administered vaccines, the younger gestation of the research study mate, or our broad inclusion requirements encompassing infants with complex medical problems (representative of the preterm population). In many industrialized nations with recognized pneumococcal immunization programs, the 13-valent pneumococcal conjugate vaccine (PCV13) has actually superseded the 7-valent pneumococcal conjugate vaccine (PCV7) and has actually been revealed to be extremely immunogenic in term infants [23,25]. The immunogenicity of PCV13 in early infants receiving a 2-3-4 and 12-month schedule was only just recently reported and exposed lower immunoglobulin G (IgG) concentrations for 8 serotypes after both primary and booster doses compared to term infants [28]. This lower immunogenicity is consistent with previous PCV7 studies [21,26] and is worrying because premature infants are likewise less likely to take advantage of the protective maternal antibodies moved throughout late pregnancy. In addition, nationwide immunization programs are increasingly consisting of reduced 2 dose priming schedules (29,30). When comparing schedules within the research study mate, the most striking finding was the contrasting immunogenicity of the 3 schedules at various time points, with the decreased dose schedule producing inferior antibody concentrations after the primary course however superior antibody concentrations after the booster dose. The higher post-primary IgG GMCs after 3 dosages (compared with 2 dosages) is consistent with 2 meta-analyses of primary schedules in term infants [31,32]. Of the 3-dose schedules, greater antibody concentrations were seen in early infants getting the extended schedule. This finding was not observed in the meta-analyses of term infant responses, however an older age at last vaccination may be more crucial in premature infants because it will allow additional maturation of their immune system [33,34]. Nevertheless, this situation has to be set against the ideal age at which protection is needed in this population. A number of research studies have shown an increased susceptibility of intrusive pneumococcal disease in infants born prematurely compared to term infants; this risk seems maximal in the very first 6 months of life [1,2,3].

4. CONCLUSION

PCV13 was well endured in early infants. Different priming schedules resulted in higher IgG concentrations at various times throughout the very first 13 months of life. We believe that such information will be beneficial to those planning or providing pneumococcal vaccines to preterm infants and will allow them to think about this finding in the context of their own immunization programs and epidemiologic circumstance, in other studies PCV-7 immunogenicity among VLBW infants, even the tiniest and least mature infants normally accomplished antibody concentrations much like those explained in full-term infants. The favorable immunogenicity of PCV-7 amongst VLBW infants supports current suggestions to immunize premature infants at the very same postnatal ages as full-term infants. In keeping with our hypothesis, nevertheless, lower birth weight appeared to be an independent risk factor for poorer vaccine immunogenicity, especially for less immunogenic serotypes. It may be particularly essential to use a timely booster dose of PCV-7 to infants who have several risk factors.

REFERENCES

[1] Rückinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis. 2010;10:12.

[2] Hjuler T, Wohlfahrt J, Simonsen J, et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis. 2007;44(8): 1051–1056.

[3] Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Effi cacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21(3):182–186.

[4] Cillóniz C1, Amaro R, Torres A. Pneumococcal vaccination. Curr Opin Infect Dis. 2016 Apr;29(2):187-96. doi: 10.1097/QCO.0000000000000246.

[5] Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy. 2005; 25(9):1193–1212

[6] Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999 –2003). Diagn Microbiol Infect Dis. 2006;56(1):69 –74

[7] Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs. 2007; 67(16):2355–2382 5. O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines on paediatric pneumococcal diseases. Am J Epidemiol. 2004;159(7):634 – 644

[8] Straetemans M, Sanders E, Veenhoven R, Schilder AG, Damoiseaux RA, Zielhuis GA. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatr Infect Dis J. 2003;22(6):515–524

[9] Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998 –2006). Vaccine. 2007;25(12):2194 –2212

[10] American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2 pt 1):362–366

[11] Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24 –59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. 2008; 57(13):343–344

[12] Liu L, Johnson HL, Cousens S, et al. Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–2161.

[13] World Health Organization and UNICEF. Global immunization data. October 2012 Available at: http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf. p. 2.

[14] Dockrell, D. H., Whyte, M. K., and Mitchell, T. J. (2012) Pneumococcal pneumonia: mechanisms of infection and resolution. Chest 142, 482-491

[15] Calbo, E., and Garau, J. (2011) Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections. Curr Opin Infect Dis 24, 241-247

[16] Calbo, E., and Garau, J. (2010) Of mice and men: innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 35, 107-113

[17] Magee, A. D., and Yother, J. (2001) Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69, 3755-3761.

[18] Cara E, Andrew P. Dobson. Bats as 'special' reservoirs for emerging zoonotic pathogens. Volume 23, Issue 3, p172–180, March 2015.

[19] Weinberger, D. M., Trzciński, K., Lu, Y. J., Bogaert, D., Brandes, A., Galagan, J., Anderson, P. W., Malley, R., and Lipsitch, M. (2009) Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 5, e1000476

[20] Esposito S, Pugni L, Bosis S. *et al* Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005231703–1708.1708.

[21] Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine. 2007;25(2):264–271.

[22] Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757–763.

[23] D'Angio CT, Heyne RJ, O'Shea TM, et al. HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE IMMUNOGENICITY IN VERY-LOW-BIRTH-WEIGHT, PREMATURE INFANTS. *The Pediatric infectious disease journal*. 2010;29(7):600-606.

[24] Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25(4):312–319.

[25] Grant LR, O'Brien SE, Burbidge P, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8(9):e74906

[26] Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127–9131

[27] Ladhani SN, Andrews NJ, Waight P, et al. Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. Vaccine. 2015;33(5):648–655

[28] Martinón-Torres F, Czajka H, Center KJ, et al. 13-Valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015;135(4). Available at: www. pediatrics. org/ cgi/ content/ full/ 135/ 4/ e876

[29] Flasche S, Van Hoek AJ, Goldblatt D, et al. The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries. PLoS Med. 2015;12(6):e1001839

[30] Findlow H, Borrow R. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom suffi cient? Hum Vaccin Immunother. 2015;11(6): 1501–1506

[31] Scott P, Rutjes AW, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine. 2011;29(52):9711–9721

[32] PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol. 2011;12(3):189–194

[33] Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9(3):185–194

[34] Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013;310(9):930–937